David earned a PhD in Biological Sciences from Columbia University in New York, NY, where he studied how Drosophila ovarian adult stem cells respond to cell signaling pathway manipulations. This work helped to redefine the organizational principles underlying adult stem cell growth models. He is currently a Science Writer, as part of the BioNews Services writing team.
GlycoMimetics announced that the first patient with advanced breast cancer has been dosed in a Phase 1b clinical trial investigating the ability of its small molecule inhibitor, GMI-1359, to stop ... Read more
A combination of the immune checkpoint inhibitor Keytruda (pembrolizumab) and the melanoma therapy Mektovi (binimetinib) is safe and well-tolerated by people with advanced triple negative breast cancer, preliminary findings ... Read more
Zymeworks announced the start of a Phase 2 trial examining its experimental cancer treatment ZW25, in combination with Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib) and the hormone therapy Faslodex (fulvestrant), ... Read more
Pin It on Pinterest